Clinical Research Directory

Inclusion Criteria: * Histologically proven stage IV non-small cell lung cancer patient * First-line treatment with chemotherapy combined with immunotherapy in the maintenance phase * Adenocarcinoma patient: maintenance with Alimta combined with pembrolizumab * Squamous cell carcinoma patient: maintenance with pembrolizumab alone * Age of at least 18 years * Performance status of 0 or 1 * Estimated life expectancy \> 12 weeks * No contraindications to respiratory rehabilitation * Adequate organ function, demonstrated by laboratory results within the last 3 weeks, allowing maintenance treatment: * Normal liver function: bilirubin \< 1.5 x ULN, ALT and AST \< 2.5 x ULN or \< 5 x ULN in the case of liver metastases. * Renal function (creatinine clearance calculation of at least \> 45 mL/min). * Hematological function: absolute neutrophil count \> 1.5 x 10\^9/L and/or platelets \> 100 x 10\^9/L, hemoglobin \> 8 g/dL. * Informed consent to participate in the study must be signed * Patient must be affiliated with or beneficiary of social security Exclusion Criteria: * Small cell lung cancer, mesothelioma, neuroendocrine lung cancer * Patients with orthopedic disorders preventing respiratory rehabilitation that, in the investigator's opinion, could interfere with respiratory rehabilitation * Unresolved toxicity from previous treatment of grade \> 1 (except alopecia) that, in the investigator's opinion, could interfere with respiratory rehabilitation * Symptomatic brain metastases (corticosteroid treatment is allowed if the doses administered are stable for at least one month before inclusion) * Bone metastases preventing respiratory rehabilitation * Contraindication to respiratory rehabilitation * Uncontrolled infection * Pregnancy and breastfeeding * Surgery within two months prior to inclusion that could interfere with respiratory rehabilitation * Persons under legal protection (guardianship or curatorship) or deprived of liberty